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Background: Propofol is used worldwide for its sedative effective; nonetheless, has the serious side effect of 
respiratory depression. An increased blood concentration of propofol is well known to be associated with increased 
respiratory depression. However, there are no studies of the effect site concentration inducing respiratory depression. 
The purpose of this study was to determine the effect site concentration inducing respiratory depression of propofol 
when sedating a patient after spinal anesthesia. 
Methods: This study included thirty seven males who received operations with spinal anesthesia, which was 
performed on L3-4 and L4-5. All patients were monitored with the bispectral index and were continuously infused 
with propofol using target controlled infusion. Respiratory depression was diagnosed when one of the following was 
evident without upper respiratory obstructive signs: a greater than 20% increase of end tidal carbon dioxide from 
baseline pressure or pulse oximetry oxygen saturation lower than 95%. We obtained the EC5, EC10, and EC50 of the 
effect site propofol for respiratory depression.
Results: The EC5 of propofol for respiratory depression was 3.09 mcg/ml (95% CI, 2.60-3.58). The EC10 of propofol for 
respiratory depression was 3.18 mcg/ml (95% CI, 2.57-3.80). The EC50 of propofol for respiratory depression was 3.99 
mcg/ml (95% CI, 2.36-5.61).
Conclusions: The EC5, EC10, and EC50 of effect site propofol for respiratory depression during spinal anesthesia were 
3.09 mcg/ml ,3.18 mcg/ml, and 3.99 mcg/ml, respectively. (Korean J Anesthesiol 2011; 61: 122-126)
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Introduction
    Propofol is widely used for anesthesia and sedation pur-
poses because of its amnesic effect, fast recovery, and low 
incidence of nausea and vomiting [1]. Propofol, however, has 
the shortcoming of severe respiratory depression, including 
a decrease in ventilatory response to hypoxia and in tidal and 
minute volumes [2]. Blouin et al. [3] reported that propofol 
increased the blood carbon dioxide tension, decreased 
the hydrogen ion concentration index, and decreased the 
ventilatory response to hypoxia.
    In a study using target-controlled infusion (TCI), Kim et al. [4] 
reported that both the frequency of airway obstruction and the 
carbon dioxide concentration in the arterial blood increased 
as the target effect site concentration increased. In the study 
conducted by Kim et al., it was estimated that the effect site 
concentrations that caused airway obstruction in 50% of the 
patients (EC50) consisting of non-smokers and smokers were 
2.6 (1.5-9.4) and 0.9 (-9.3) μg/ml, respectively. The results 
of the study conducted by Kim et al., however, include airway 
obstruction as well as respiratory depression, such as apnea.
    It has been observed that in the case of the infusion of 
propofol for sedation after regional anesthesia in the actual 
operating room, if the sensitivity to propofol is weak, or if 
the excessive movement of the patient even after anesthesia 
interferes with the surgical operation, the dose of propofol is 
sometimes increased while airway obstruction is rectified via 
triple airway maneuver. As such, this study was conducted 
to determine the effect site concentration of propofol at 
which respiratory depression would occur regardless of 
airway obstruction in the case of the continuous infusion of 
propofol using TCI, by assuming that the airway-obstructing 
propofol dose and the respiratory-depressing propofol dose 
are different when propofol is used for a patient who breathes 
spontaneously.
Meterials and Methods
    The study included 37 patients aged 20 to 65 years old, who 
were classified as status 1 or 2 according to the Physical-Status 
Classification of the American Society of Anesthesiologists, and 
who were to receive surgery under spinal anesthesia (Table 1). 
    Approval was obtained from the Ethics Committee for Clinical 
Trials, and informed consent was obtained from each of the 
patients. Excluded from the study were patients who were 
obese, who had a body mass index (BMI) of 30 or above, who 
were Mallampatti class III or above, or who showed hearing 
loss, a history of sedative use, or a history of sleep apnea, 
respiratory disease, or upper-respiratory infection within the 
past three weeks. No drug was administered before anesthesia.
    Upon each patient’s arrival at the operating room, spinal 
anesthesia was performed on L3-4 and L4-5 in the lateral 
recumbent position while the electrocardiogram, blood pressure 
(BP), and peripheral arterial oxygen saturation were being 
monitored. The patients whose sensory-extinction levels were 
T6 or above when tested with an alcohol swab were excluded 
from the study. Oxygen (5 L/min) was supplied through the 
nasal cavity, and the end-expiratory carbon dioxide tension was 
monitored through one of the nostrils.
    After ensuring that an adequate level of anesthesia was 
obtained, intravenous infusion of 2% lidocaine (40 mg) was 
given, and propofol was continuously intravenously infused 
using a target-controlled infusion system (Base Prima Orchestra, 
Fresenius Vial, France). The target effect site concentration was 
determined for each patient, using the Schnidr model. 
    The target effect site concentration was determined using 
the up-and-down method. For the first patient in the study, 
the initial target effect site concentration was 2 mcg/ml. 
When respiratory depression occurred, the target effect site 
concentration was reduced by 0.2 mcg/ml for the next patient. 
In contrast, when no respiratory depression occurred, the target 
effect site concentration of the previous patient was increased 
by 0.2 mcg/ml for the next patient.
    Ten minutes after the propofol concentration reached the 
target effect site concentration, the bispectral index (BIS), 
oxygen saturation, and end-expiratory carbon dioxide tension 
were recorded with 30-second intervals, and the pulse rate, 
respiratory rate, and BP were measured. 
    When airway obstruction occurred before or after the propofol 
concentration reached the target effect site concentration, the 
aforementioned variables were measured after waiting for at 
least 3 minutes and after checking that no airway obstruction 
occurred after repositioning the patient or inserting an oral 
airway. Here, airway obstruction was defined as a case in which 
end-expiratory carbon dioxide tension was not detected for 
10 seconds or more based on the accompanying snoring or 
spurasternal notch, air flow was not detected, and the airway 
could be maintained via a three-way airway maneuver.
    When the average arterial BP was 60 mmHg or less or 
decreased by 30% or more from the baseline BP, 4 mg ephedrine 
was intravenously injected. When the heart rate was 45 beats 
or less per minute, 0.5 mg atrophine sulfate was intravenously 
injected.
Table 1. Patients’ Demographic Data
Age (year) 37.18 ± 13.42
Height (cm)
Weight (kg)
Body mass index
171.81 ± 6.94
70.32 ± 13.54
24.14 ± 2.76124 www.ekja.org
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    Respiratory depression was defined as the case in which the 
end-expiratory carbon dioxide tension increased by 20% or 
more from the pre-sedation end-expiratory carbon dioxide 
tension without upper-airway obstruction symptoms, or in 
which the oxygen saturation decreased to below 95%.
    The patients’ ages, heights, weights, and BMIs were expressed 
as mean±SD, and the estimated effect site concentrations at 
which respiratory depression would occur in 5% (EC5), 10% 
(EC10), and 50% (EC50) of the patients was determined by 
estimating the centered isotonic regression and PAVA using R: 
A Language and Environmental for Statistical Computing (ver. 
2.11.1, R Foundation for Statistical Computing, Vienna, Austria). 
The BIS value by the target effect site concentration of propofol 
was tested using the Pearson correlation coefficient.
Results 
    In all the patients, the blocking level of the sensory nerve after 
spinal anesthesia was below T8. Respiratory depression did not 
occur at the propofol concentration of 3.6 mcg/ml but occurred 
in three of seven patients at 3.8 mcg/ml, in four of seven 
patients at 4.0 mcg/ml, in three of six patients at 4.2 mch/ml, 
and in one patient at 4.6 mcg/ml (Fig. 1). Thus, the estimated 
effect site concentration of propofol that could cause respiratory 
depression in 5% (EC5) of the patients was 3.9 mcg/ml (95% CI, 
2.60-3.58), 3.18 mcg/ml in 10% (EC10) of the patients (95% CI, 
2.57-3.80), and 3.99 mcg/ml in 50% (EC50) of the patients (95% 
CI, 2.36-5.61) (Fig. 2).
    Upper-airway obstruction occurred in 16 patients; among 
them, it occurred at the effect site concentration of 3.6 mcg/
ml or less in five patients, and the effect site concentrations at 
which upper-airway obstruction occurred ranged from 2.0 mcg/
ml to 4.4 mcg/ml.
    In the patients in whom upper-airway obstruction occurred, 
respiration was maintained by performing a three-way airway 
maneuver or by using an airway maintenance device after 
repositioning the body.
    In one patient who received 4.0 mcg/ml propofol, an 
adequate sedative effect was not achieved because the BIS was 
90 or more. No correlation was found between the propofol 
concentration and BIS (Fig. 3). In none of the patients did 
the heart rate drop below 45 bpm or less. At the effect site 
concentrations of 2.0 mcg/ml in one patient and 3.8 mcg/ml 
in one patient, ephedrine was intravenously infused as the BP 
dropped by 30% or more from the baseline.
Discussion
    Propofol is widely used for anesthesia and sedation because 
Fig. 1. Individual responses to the pre-determined effect site con-
centration of propofol.
Fig. 2. Relationship between respiratory depression and the effect 
site concentration of propofol. EC5 value was 3.09 mcg/ml and EC50 
value was 3.99 mcg/ml.
Fig. 3. The mean BIS value to the target concentration of propofol. 
The correlation between BIS and effect site concentration of propofol 
was not significant (P > 0.05).125 www.ekja.org
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of its advantages in allowing for fast recovery and a low 
occurrence rate of nausea and vomiting. An increase in the 
effect site concentration of propofol, however, can cause airway 
obstruction, respiratory depression, hypoxia, or an unstable 
hemodynamic response [5].
    Propofol at a sedative dose can induce a decrease in the tidal 
volume, an increase in the respiratory rate, and a decrease in 
the inspiration cycle [2]. It is also known to cause ventilatory 
depression, such as a decreased ventilatory response or 
decreased heart beat response to hypoxia [6]. Yamakage et al. 
[7] reported that when sedation was performed with propofol, 
the tidal volume decreased by 60%, and arterial-oxygen tension 
occurred due to paradoxical breathing caused by upper-airway 
obstruction.
    Although the neurological mechanism by which propofol 
causes central-respiratory depression remains unclear, a study 
using a mouse reported that the GABA-receptor-mediated 
hyperpolarization of the pre-inspiratory neurons was involved 
in such a mechanism [8].
    Vuyk et al. [9] reported that when propofol was solely used 
without premedication, the serum effect site concentration of 
porpofol required for inducing loss of consciousness in 50% 
and 60% of the patients were 3.4 and 4.3 mcg/ml, respectively. 
Nishiyama [10] reported that the effect site concentration that 
induces loss of consciousness after spinal anesthetization is 
1.9 mcg/ml, and that the effect site concentration for proper 
sedation is 1.0-1.8 mcg/ml.
    In this study, the effect site concentration that induced 
respiratory depression was 3.8 mcg/ml, and the EC5, EC10, and 
EC50 values that induced respiratory depression were 3.09, 
3.18, and 3.99 mcg/ml, respectively. This shows that respiratory 
depression occurs at a certain concentration level of propofol, 
which is the same or higher than that required for spinal 
sedation [10].
    This study also showed that respiratory depression that 
cannot be rectified via a three-way airway maneuver can occur 
at the effect site concentration of propofol that was identified 
by Kim et al. [4] to cause upper-airway obstruction. Pollock 
et al. [11] observed a decrease in the BIS value after spinal 
anesthetization, and reported that spinal anesthetization is 
related to the sedative effect of propofol. In addition, Ozkan-
Seyhan et al. [12] reported that the dose of propofol required for 
inducing a loss of consciousness decreases as the anesthesia 
level increases in spinal anesthetization.
    It is believed that spinal anesthesia can influence the effect 
site concentration as it plays a role in sedation. The limitation 
of this study is that the estimated effect site concentration 
that causes respiratory depression is restricted to patients 
who received spinal anesthesia, because all the study subjects 
received spinal anesthesia.
    Kil et al. [13] reported that BIS was significantly related 
with respiratory depression according to the effect site 
concentration of propofol, and that the BIS value was 41.1 ± 
2.5 when the effect site concentration of propofol was 3.5 mcg/
ml in Koreans. In this study, the BIS value ranged from 80 to 
40 at the propofol concentrations of 2.0-4.6 mcg/ml, and no 
significant correlation was observed between BIS and propofol 
concentration. This is believed to be due to the small number of 
samples of the effect site concentration of propofol.
    As this study was conducted to determine the effect site 
concentration of propofol that could induce respiratory 
depression using the up-and-down method, the effect 
site concentration that could cause sedation could not be 
determined. In addition, as the propofol concentration that is 
used only for sedation purposes but that could cause respiratory 
depression was not studied in patients who did not receive 
regional anesthesia, further studies are required for such.
    In conclusion, the effect site concentrations of propofol that 
are used for sedation purposes via spinal anesthesization are 
3.09, 3.18, and 3.99 mcg/ml for EC5, EC10, and EC50, respectively.
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